Understanding primary aldosteronism: Impact of next generation sequencing and expression profiling

Molecular and Cellular Endocrinology

Volumn 399, Issue , 2015, Pages 311-320

  Monticone, Silvia ^a   Else, Tobias ^b   Mulatero, Paolo ^a   Williams, Tracy A ^a   Rainey, William E ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

ATP1A1; ATP2B3; CACNA1D; Exome sequencing; KCNJ5; Primary aldosteronism

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALDOSTERONE; ALDOSTERONE SYNTHASE; AMILORIDE; AMLODIPINE; BETA CATENIN; CALCIUM CHANNEL L TYPE; COMPLEMENTARY DNA; G PROTEIN ACTIVATED INWARD RECTIFIER POTASSIUM CHANNEL 4; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; PLASMA MEMBRANE CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 3; POTASSIUM; SODIUM POTASSIUM ADENOSINE TRIPHOSPHATASE SUBUNIT ALPHA 1; SPIRONOLACTONE; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT L TYPE CALCIUM CHANNEL SUBUNIT ALPHA 1D;

ADRENAL CORTEX ADENOMA; ADRENAL HYPERPLASIA; ADRENALECTOMY; ALDOSTERONE RELEASE; AMINO ACID SUBSTITUTION; ATP1A1 GENE; ATP2B3 GENE; CACNA1D GENE; DEVELOPMENTAL DISORDER; FAMILIAL DISEASE; FAMILIAL HYPERALDOSTERONISM TYPE III; GENE; GENE EXPRESSION PROFILING; GERMLINE MUTATION; HUMAN; HYPERTENSION; KCNJ5 GENE; MEMBRANE POTENTIAL; MISSENSE MUTATION; NEXT GENERATION SEQUENCING; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; POINT MUTATION; PRIMARY HYPERALDOSTERONISM; REVIEW; SEQUENCE ANALYSIS; SOMATIC MUTATION; STEROIDOGENESIS; WNT SIGNALING PATHWAY; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; HYPERALDOSTERONISM; METABOLISM;

ALDOSTERONE; ANIMALS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; HYPERALDOSTERONISM;

EID: 84910119272     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2014.09.015     Document Type: Review

References (103)

1. Al-Salameh A., Cohen R., Desailloud R. Overview of the genetic determinants of primary aldosteronism. Appl. Clin. Genet 2014, 7:67-79.
2. Albiger N.M., Sartorato P., Mariniello B., Iacobone M., Finco I., Fassina A., et al. A case of primary aldosteronism in pregnancy: do LH and GNRH receptors have a potential role in regulating aldosterone secretion?. Eur. J. Endocrinol 2011, 164:405-412.
3. Assié G., Auzan C., Gasc J.M., Baviera E., Balaton A., Elalouf J.M., et al. Steroidogenesis in aldosterone-producing adenoma revisited by transcriptome analysis. J. Clin. Endocrinol. Metab 2005, 90:6638-6649.
4. Azizan E.A., Lam B.Y., Newhouse S.J., Zhou J., Kuc R.E., Clarke J., et al. Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa- and zona fasciculata-like tumors. J. Clin. Endocrinol. Metab 2012, 97:E819-E829.
5. Azizan E.A., Murthy M., Stowasser M., Gordon R., Kowalski B., Xu S., et al. Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension 2012, 59:587-591.
6. Azizan E.A., Poulsen H., Tuluc P., Zhou J., Clausen M.V., Lieb A., et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat. Genet 2013, 45:1055-1060.
7. Åkerström T., Crona J., Delgado Verdugo A., Starker L.F., Cupisti K., Willenberg H.S., et al. Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PLoS ONE 2012, 7:E41926.
8. Bandulik S., Penton D., Barhanin J., Warth R. TASK1 and TASK3 potassium channels: determinants of aldosterone secretion and adrenocortical zonation. Horm. Metab. Res 2010, 42:450-457.
9. Bassett M.H., Zhang Y., Clyne C., White P.C., Rainey W.E. Differential regulation of aldosterone synthase and 11beta-hydroxylase transcription by steroidogenic factor-1. J. Mol. Endocrinol 2002, 28:125-135.
10. Bassett M.H., White P.C., Rainey W.E. A role for the NGFI-B family in adrenal zonation and adrenocortical disease. Endocr. Res 2004, 30:567-574.
11. Bassett M.H., Mayhew B., Rehman K., White P.C., Mantero F., Arnaldi G., et al. Expression profiles for steroidogenic enzymes in adrenocortical disease. J. Clin. Endocrinol. Metab 2005, 90:5446-5455.
12. Berthon A., Sahut-Barnola I., Lambert-Langlais S., de Joussineau C., Damon-Soubeyrand C., Louiset E., et al. Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum. Mol. Genet 2010, 19:1561-1576.
13. Berthon A., Martinez A., Bertherat J., Val P. Wnt/β-catenin signalling in adrenal physiology and tumour development. Mol. Cell. Endocrinol 2012, 351:87-95.
14. Berthon A., Drelon C., Ragazzon B., Boulkroun S., Tissier F., Amar L., et al. WNT/β-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production. Hum. Mol. Genet 2014, 23:889-905.
15. Beuschlein F., Boulkroun S., Osswald A., Wieland T., Nielsen H.N., Lichtenauer U.D., et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat. Genet 2013, 45:440-444.
16. Boulkroun S., Samson-Couterie B., Dzib J.F., Lefebvre H., Louiset E., Amar L., et al. Adrenal cortex remodeling and functional zona glomerulosa hyperplasia in primary aldosteronism. Hypertension 2010, 56:885-892.
17. Boulkroun S., Samson-Couterie B., Golib-Dzib J.F., Amar L., Plouin P.F., Sibony M., et al. Aldosterone-producing adenoma formation in the adrenal cortex involves expression of stem/progenitor cell markers. Endocrinology 2011, 152:4753-4763.
18. Boulkroun S., Beuschlein F., Rossi G.P., Golib-Dzib J.F., Fischer E., Amar L., et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 2012, 59:592-598.
19. Boulkroun S., Golib Dzib J.F., Samson-Couterie B., Rosa F.L., Rickard A.J., Meatchi T., et al. KCNJ5 mutations in aldosterone producing adenoma and relationship with adrenal cortex remodeling. Mol. Cell. Endocrinol 2013, 371:221-227.
20. Braunewell K.H., Klein-Szanto A.J. Visinin-like proteins (VSNLs): interaction partners and emerging functions in signal transduction of a subfamily of neuronal Ca2+ -sensor proteins. Cell Tissue Res 2009, 335:301-316.
21. Carroll J., Dluhy R., Fallo F., Pistorello M., Bradwin G., Gomez-Sanchez C.E., et al. Aldosterone-producing adenomas do not contain glucocorticoid-remediable aldosteronism chimeric gene duplications. J. Clin. Endocrinol. Metab 1996, 81:4310-4312.
22. Cartier D., Jégou S., Parmentier F., Lihrmann I., Louiset E., Kuhn J.M., et al. Expression profile of serotonin4 (5-HT4) receptors in adrenocortical aldosterone-producing adenomas. Eur. J. Endocrinol 2005, 153:939-947.
23. Catena C., Colussi G., Nadalini E., Chiuch A., Baroselli S., Lapenna R., et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch. Intern. Med 2008, 168:80-85.
24. + channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011, 331:768-772.
25. Clyne C.D., Zhang Y., Slutsker L., Mathis J.M., White P.C., Rainey W.E. Angiotensin II and potassium regulate human CYP11B2 transcription through common cis-elements. Mol. Endocrinol 1997, 11:638-649.
26. Conn J.W. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J. Lab. Clin. Med 1955, 45:3-17.
27. Davies E., Kenyon C.J. CYP11B2 polymorphisms and cardiovascular risk factors. J. Hypertens 2003, 21:1249-1253.
28. Davies L.A., Hu C., Guagliardo N.A., Sen N., Chen X., Talley E.M., et al. TASK channel deletion in mice causes primary hyperaldosteronism. Proc. Natl Acad. Sci. U.S.A. 2008, 105:2203-2208.
29. Eid J., Fehr A., Gray J., Luong K., Lyle J., Otto G., et al. Real-time DNA sequencing from single polymerase molecules. Science 2009, 323:133-138.
30. El Wakil A., Lalli E. The Wnt/beta-catenin pathway in adrenocortical development and cancer. Mol. Cell. Endocrinol 2011, 332:32-37.
31. El Wakil A., Bandulik S., Guy N., Bendahhou S., Zennaro M.C., Niehrs C., et al. Dkk3 is a component of the genetic circuitry regulating aldosterone biosynthesis in the adrenal cortex. Hum. Mol. Genet 2012, 21:4922-4929.
32. Else T., Williams A.R., Sabolch A., Jolly S., Miller B.S., Hammer G.D. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J. Clin. Endocrinol. Metab 2014, 99:455-461.
33. Enberg U., Volpe C., Hoog A., Wedell A., Farnebo L.O., Thoren M., et al. Postoperative differentiation between unilateral adrenal adenoma and bilateral adrenal hyperplasia in primary aldosteronism by mRNA expression of the gene CYP11B2. Eur. J. Endocrinol 2004, 151:73-85.
34. Fallo F., Pezzi V., Barzon L., Mulatero P., Veglio F., Sonino N., et al. Quantitative assessment of CYP11B1 and CYP11B2 expression in aldosterone-producing adenomas. Eur. J. Endocrinol 2002, 147:795-802.
35. Fallo F., Veglio F., Bertello C., Sonino N., Della Mea P., Ermani M., et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J. Clin. Endocrinol. Metab 2006, 91:454-459.
36. Fernandes-Rosa F.L., Williams T.A., Riester A., Steichen O., Beuschlein F., Boulkroun S., et al. Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. Hypertension 2014, 64:354-361.
37. Ferraz-de-Souza B., Hudson-Davies R.E., Lin L., Parnaik R., Hubank M., Dattani M.T., et al. Sterol O-acyltransferase 1 (SOAT1, ACAT) is a novel target of steroidogenic factor-1 (SF-1, NR5A1, Ad4BP) in the human adrenal. J. Clin. Endocrinol. Metab 2011, 96:E663-E668.
38. Fischer E., Beuschlein F. Novel genes in primary aldosteronism. Curr. Opin. Endocrinol. Diabetes Obes 2014, 21:154-158.
39. Funder J.W., Carey R.M., Fardella C., Gomez-Sanchez C.E., Mantero F., Stowasser M., et al. Case detection, diagnosis and treatment of patients with primary aldosteronism: an endocrine society clinical practice guidelines. J. Clin. Endocrinol. Metab 2008, 93:3266-3281.
40. Ganguly A. Primary aldosteronism. N. Engl. J. Med 1998, 339:1828-1834.
41. Geller D.S., Zhang J., Wisgerhof M.V., Shackleton C., Kashgarian M., Lifton R.P. A novel form of human Mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J. Clin. Endocrinol. Metab 2008, 93:3117-3123.
42. Gomez-Sanchez C.E., Gomez-Sanchez E.P. Mutations of the potassium channel KCNJ5 causing aldosterone-producing adenomas: one or two hits?. Hypertension 2012, 59:196-197.
43. Hattangady N.G., Olala L.O., Bollag W.B., Rainey W.E. Acute and chronic regulation of aldosterone production. Mol. Cell. Endocrinol 2012, 350:151-162.
44. Heikkila M., Peltoketo H., Leppaluoto J., Ilves M., Vuolteenaho O., Vainio S. Wnt-4 deficiency alters mouse adrenal cortex function, reducing aldosterone production. Endocrinology 2002, 143:4358-4365.
45. Heitzmann D., Derand R., Jungbauer S., Bandulik S., Sterner C., Schweda F., et al. Invalidation of TASK1 potassium channels disrupts adrenal gland zonation and mineralocorticoid homeostasis. EMBO J. 2008, 27:179-187.
46. Hibino H., Inanobe A., Furutani K., Murakami S., Findlay I., Kurachi Y. Inwardly rectifying potassium channels: their structure, function, and physiological roles. Physiol. Rev 2010, 90:291-366.
47. Kim A., Giordano T.J., Kuick R., Serecky K., Hammer G.D. Wnt/β-catenin signaling in adrenocortical stem/progenitor cells: implications for adrenocortical carcinoma. Ann. Endocrinol. (Paris) 2009, 70:156.
48. Krapivinsky G., Gordon E.A., Wickman K., Velimirovic B., Krapivinsky L., Clapham D.E. The G-protein-gated atrial K + channel IKACh is a heteromultimer of two inwardly rectifying K(+)-channel proteins. Nature 1995, 374:135-141.
49. Kuppusamy M., Caroccia B., Stindl J., Bandulik S., Lenzini L., Gioco F., et al. A novel KCNJ5-insT149 somatic mutation close to, but outside, the selectivity filter causes resistant hypertension by loss of selectivity for potassium. J. Clin. Endocrinol. Metab 2014, [Epub ahead of print].
50. Kurachi Y., Tung R.T., Ito H., Nakajima T. G protein activation of cardiac muscarinic K + channels. Prog. Neurobiol 1992, 39:229-246.
51. Lacroix A., Baldacchino V., Bourdeau I., Hamet P., Tremblay J. Cushing's syndrome variants secondary to aberrant hormone receptors. Trends Endocrinol. Metab 2004, 15:375-382.
52. Lefebvre H., Cartier D., Duparc C., Lihrmann I., Contesse V., Delarue C., et al. Characterization of serotonin(4) receptors in adrenocortical aldosterone-producing adenomas: in vivo and in vitro studies. J. Clin. Endocrinol. Metab 2002, 87:1211-1216.
53. Lenzini L., Seccia T.M., Aldighieri E., Belloni A.S., Bernante P., Giuliani L., et al. Heterogeneity of aldosterone producing adenomas revealed by a whole transcriptome analysis. Hypertension 2007, 50:1106-1113.
54. +channel 2 (TASK-2) gene is a hallmark of aldosterone producing adenoma causing human primary aldosteronism. J. Clin. Endocrinol. Metab 2013, 99:E674-E682.
55. Li N.F., Li H.J., Zhang D.L., Zhang J.H., Yao X.G., Wang H.M., et al. Genetic variations in the KCNJ5 gene in primary aldosteronism patients from Xinjiang, China. PLoS ONE 2013, 8:e54051.
56. Lifton R.P., Dluhy R.G., Powers M., Rich G.M., Cook S., Ulick S., et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992, 355:262-265.
57. Linden A.M., Aller M.I., Leppä E., Rosenberg P.H., Wisden W., Korpi E.R. K + channel TASK-1 knockout mice show enhanced sensitivities to ataxic and hypnotic effects of GABA(A) receptor ligands. J. Pharmacol. Exp. Ther 2008, 327:277-286.
58. Mardis E.R. A decade's perspective on DNA sequencing technology. Nature 2011, 470:198-203.
59. Marionneau C., Couette B., Liu J., Li H., Mangoni M.E., Nargeot J., et al. Specific pattern of ionic channel gene expression associated with pacemaker activity in the mouse heart. J. Physiol 2005, 562:223-234.
60. McManus F., Sands W., Diver L., MacKenzie S.M., Fraser R., Davies E., et al. APEX1 regulation of aldosterone synthase gene transcription is disrupted by a common polymorphism in humans. Circ. Res 2012, 111:212-219.
61. Metzker M.L. Sequencing technologies - the next generation. Nat. Rev. Genet 2010, 11:31-46.
62. Milliez P., Girerd X., Plouin P.F., Blacher J., Safar M.E., Mourad J.J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol 2005, 45:1243-1248.
63. Monticone S., Hattangady N.G., Nishimoto K., Mantero F., Rubin B., Cicala M.V., et al. Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. J. Clin. Endocrinol. Metab 2012, 97:E1567-E1572.
64. Monticone S., Hattangady N.G., Penton D., Isales C.M., Edwards M.A., Williams T.A., et al. A novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III. J. Clin. Endocrinol. Metab 2013, 98:E1861-E1865.
65. Moseley A.E., Huddleson J.P., Bohanan C.S., James P.F., Lorenz N.J., Aronow B.J., et al. Genetic profiling reveals global changes in multiple biological pathways in the hearts of Na,K-ATPase α1 isoform haploinsufficient mice. Cell. Physiol. Biochem 2005, 15:145-158.
66. Mulatero P., Veglio F., Pilon C., Rabbia F., Zocchi C., Limone P., et al. Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. J. Clin. Endocrinol. Metab 1998, 83:2573-2575.
67. Mulatero P., Schiavone D., Fallo F., Rabbia F., Pilon C., Chiandussi L., et al. CYP11B2 gene polymorphisms in idiopathic hyperaldosteronism. Hypertension 2000, 35:694-698.
68. Mulatero P., Williams T.A., Milan A., Paglieri C., Rabbia F., Fallo F., et al. Blood pressure in patients with primary aldosteronism is influenced by bradykinin B(2) receptor and alpha-adducin gene polymorphisms. J. Clin. Endocrinol. Metab 2002, 87:3337-3343.
69. Mulatero P., Stowasser M., Loh K.C., Fardella C.E., Gordon R.D., Mosso L., et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J. Clin. Endocrinol. Metab 2004, 89:1045-1050.
70. Mulatero P., Morello F., Veglio F. Genetics of primary aldosteronism. J. Hypertens 2004, 22:663-670.
71. Mulatero P., Milan A., Williams T.A., Veglio F. Mineralocorticoid receptor blockade in the protection of target organ damage. Cardiovasc. Hematol. Agents Med. Chem 2006, 4:75-91.
72. Mulatero P., Tizzani D., Viola A., Bertello C., Monticone S., Mengozzi G., et al. Prevalence and characteristics of familial hyperaldosteronism : the PATOGEN Study (Primary Aldosteronism in TOrino-GENetic forms). Hypertension 2011, 58:797-803.
73. Mulatero P., Tauber P., Zennaro M.C., Monticone S., Lang K., Beuschlein F., et al. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension 2012, 59:235-240.
74. Mulatero P., Monticone S., Bertello C., Viola A., Tizzani D., Iannaccone A., et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J. Clin. Endocrinol. Metab 2013, 98:4826-4833.
75. Mulatero P., Monticone S., Rainey W.E., Veglio F., Williams T.A. Role of KCNJ5 in familial and sporadic primary aldosteronism. Nat. Rev. Endocrinol 2013, 9:104-112.
76. Murthy M., Azizan E.A., Brown M.J., O'Shaughnessy K.M. Characterization of a novel somatic KCNJ5 mutation delI157 in an aldosterone-producing adenoma. J. Hypertens 2012, 30:1827-1833.
77. Murthy M., Xu S., Massimo G., Wolley M., Gordon R.D., Stowasser M., et al. Role for germline mutations and a rare coding single nucleotide polymorphism within the KCNJ5 potassium channel in a large cohort of sporadic cases of primary aldosteronism. Hypertension 2014, 63:783-789.
78. Nakamura Y., Hattangady N.G., Ye P., Satoh F., Morimoto R., Ito-Saito T., et al. Aberrant gonadotropin-releasing hormone receptor (GnRHR) expression and its regulation of CYP11B2 expression and aldosterone production in adrenal aldosterone-producing adenoma (APA). Mol. Cell. Endocrinol 2014, 385:102-108.
79. Nogueira E.F., Gerry D., Mantero F., Mariniello B., Rainey W.E. The role of TASK1 in aldosterone production and its expression in normal adrenal and aldosterone-producing adenomas. Clin. Endocrinol. (Oxf) 2010, 73:22-29.
80. Oki K., Plonczynski M.W., Lam M.L., Gomez-Sanchez E.P., Gomez-Sanchez C.E. The potassium channel, Kir3.4 participates in angiotensin II-stimulated aldosterone production by a human adrenocortical cell line. Endocrinology 2012, 153:4328-4335.
81. Oki K., Plonczynski M.W., Luis Lam M., Gomez-Sanchez E.P., Gomez-Sanchez C.E. Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis. Endocrinology 2012, 153:1774-1782.
82. Perraudin V., Delarue C., Lefebvre H., Do Rego J.L., Vaudry H., Kuhn J.M. Evidence for a role of vasopressin in the control of aldosterone secretion in primary aldosteronism: in vitro and in vivo studies. J. Clin. Endocrinol. Metab 2006, 91:1566-1572.
83. Portrat-Doyen S., Tourniaire J., Richard O., Mulatero P., Aupetit-Faisant B., Curnow K.M., et al. Isolated aldosterone synthase deficiency caused by simultaneous E198D and V386A mutations in the CYP11B2 gene. J. Clin. Endocrinol. Metab 1998, 83:4156-4161.
84. Saner-Amigh K., Mayhew B.A., Mantero F., Schiavi F., White P.C., Rao C.V., et al. Elevated expression of luteinizing hormone receptor in aldosterone-producing adenomas. J. Clin. Endocrinol. Metab 2006, 91:1136-1142.
85. Savard S., Amar L., Plouin P.F., Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension 2013, 62:331-336.
86. Scholl U.I., Nelson-Williams C., Yue P., Grekin R., Wyatt R.J., Dillon M.J., et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc. Natl Acad. Sci. U.S.A. 2012, 109:2533-2538.
87. Scholl U.I., Goh G., Stölting G., de Oliveira R.C., Choi M., Overton J.D., et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat. Genet 2013, 45:1050-1054.
88. So A., Duffy D.L., Gordon R.D., Jeske Y.W., Lin-Su K., New M.I., et al. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J. Hypertens 2005, 23:1477-1484.
89. Su H., Gu Y., Li F., Wang Q., Huang B., Jin X., et al. The PI3K/AKT/mTOR signaling pathway is overactivated in primary aldosteronism. PLoS ONE 2013, 8(4):e62399.
90. Sukor N., Mulatero P., Gordon R.D., So A., Duffy D., Bertello C., et al. Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families. J. Hypertens 2008, 26:1577-1582.
91. Taguchi R., Yamada M., Nakajima Y., Satoh T., Hashimoto K., Shibusawa N., et al. Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas. J. Clin. Endocrinol. Metab 2012, 97:1311-1319.
92. Therien B., Mellinger R.C., Caldwell J.R., Howard P.J. Primay aldosteronism due to adrenal hyperplasia. AMA J. Dis. Child 1959, 98:90-99.
93. Wang T., Satoh F., Morimoto R., Nakamura Y., Sasano H., Auchus R.J., et al. Gene expression profiles in aldosterone-producing adenomas and adjacent adrenal glands. Eur. J. Endocrinol 2011, 164:613-619.
94. Wickman K., Nemec J., Gendler S.J., Clapham D.E. Abnormal heart rate regulation in GIRK4 knockout mice. Neuron 1998, 20:103-114.
95. Wickman K., Karschin C., Karschin A., Picciotto M.R., Clapham D.E. Brain localization and behavioral impact of the G-protein-gated K + channel subunit GIRK4. J. Neurosc 2000, 20:5608-5615.
96. Williams T.A., Monticone S., Morello F., Liew C.C., Mengozzi G., Pilon C., et al. Teratocarcinoma-derived growth factor-1 is upregulated in aldosterone-producing adenomas and increases aldosterone secretion and inhibits apoptosis in vitro. Hypertension 2010, 55:1468-1475.
97. Williams T.A., Monticone S., Crudo V., Warth R., Veglio F., Mulatero P. Visinin-like 1 is upregulated in aldosterone-producing adenomas with KCNJ5 mutations and protects from calcium-induced apoptosis. Hypertension 2012, 59:833-839.
98. Williams T.A., Monticone S., Schack V.R., Stindl J., Burrello J., Buffolo F., et al. Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas. Hypertension 2014, 63:188-195.
99. Wu V.C., Wu C.K., Chang Y.C., Young G.H., Chen S.C., Yang W.S., et al. TAIPAI study group. Association of the variations in the HSD3β gene with primary aldosteronism. J. Hypertens 2013, 31:1396-1405.
100. Ye P., Mariniello B., Mantero F., Shibata H., Rainey W.E. G-protein-coupled receptors in aldosterone-producing adenomas: a potential cause of hyperaldosteronism. J. Endocrinol 2007, 195:39-48.
101. Yingst D.R., Davis J., Krenz S., Schiebinger R.J. Insights into the mechanism by which inhibition of Na,K-ATPase stimulates aldosterone production. Metabolism 1999, 48:1167-1171.
102. Zennaro M.C., Jeunemaitre X., Boulkroun S. Integrating genetics and genomics in primary aldosteronism. Hypertension 2012, 60:580-588.
103. Zwermann O., Suttmann Y., Bidlingmaier M., Beuschlein F., Reincke M. Screening for membrane hormone receptor expression in primary aldosteronism. Eur. J. Endocrinol 2009, 160:443-451.